Impact of Relative Dose Intensity of Enfortumab Vedotin for Advanced Urothelial Carcinoma
Despite frequent dose reductions and interruptions required to manage treatment-emergent AEs during EV therapy, these adjustments did not significantly impair the drug's efficacy in patients with advanced UC.
Authors
- Manabu Mochida
- Takahito Negishi (ORCID: https://orcid.org/0000-0002-6645-8829)
- Aki Kijima
- Nobuki Furubayashi (ORCID: https://orcid.org/0000-0001-9159-493X)
- Hideo Katsuki
- Motonobu Nakamura (ORCID: https://orcid.org/0000-0003-3038-1361)
Institutions
- National Hospital Organization Kyushu Cancer Center (JP)
Publication Details
- Journal
- In Vivo
- Published
- 2024-12-31
- DOI
- https://doi.org/10.21873/invivo.13843
- Citations
- 4
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.29